C3L-02165
— · cohortA2
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortA2
- subtype
- cohortA2
- age_years
- 64.79397673
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- ANGIOGENESIS+0.390
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.260
- TGF_BETA_SIGNALING+0.250
- MYOGENESIS+0.240
- PANCREAS_BETA_CELLS+0.220
- HEDGEHOG_SIGNALING+0.160
- KRAS_SIGNALING_DN+0.150
- UV_RESPONSE_DN+0.110
- COAGULATION+0.040
- WNT_BETA_CATENIN_SIGNALING+0.040
Top 10 suppressed
- INTERFERON_ALPHA_RESPONSE-0.610
- MYC_TARGETS_V2-0.600
- E2F_TARGETS-0.550
- G2M_CHECKPOINT-0.550
- MYC_TARGETS_V1-0.550
- INTERFERON_GAMMA_RESPONSE-0.520
- MTORC1_SIGNALING-0.510
- INFLAMMATORY_RESPONSE-0.400
- IL6_JAK_STAT3_SIGNALING-0.370
- MITOTIC_SPINDLE-0.350
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-CN-4737-01A-01R-1436-07 | — | — | 0.919 |
| 2 | SRR8518225 | — | B | 0.911 |
| 3 | TCGA-A7-A5ZX-01A-12R-A29R-07 | — | A | 0.903 |
| 4 | SRR1313111 | — | A | 0.901 |
| 5 | C3N-01409 | — | cohortA1 | 0.897 |
| 6 | TCGA-CV-7103-01A-21R-2016-07 | — | — | 0.892 |
| 7 | TCGA-78-7161-01A-11R-2039-07 | — | cohortA3 | 0.889 |
| 8 | C3L-03463 | — | cohortA3 | 0.882 |
| 9 | e3d71c3f-4e56-45fa-be88-2cf444b70a5c | — | — | 0.881 |
| 10 | C3L-01890 | — | cohortA2 | 0.877 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 12 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| ANGIOGENESIS | 0.390 | Remibrutinib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.260 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.250 | Inavolisib | — uncovered |
| MYOGENESIS | 0.240 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.220 | Cobimetinib | — uncovered |
| HEDGEHOG_SIGNALING | 0.160 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.150 | Remibrutinib | — uncovered |
| UV_RESPONSE_DN | 0.110 | Inavolisib | — uncovered |
| COAGULATION | 0.040 | Binimetinib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.040 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.020 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.010 | Inavolisib | — uncovered |